231 related articles for article (PubMed ID: 12062286)
1. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
Filosso PL; Ruffini E; Oliaro A; Papalia E; Donati G; Rena O
Eur J Cardiothorac Surg; 2002 May; 21(5):913-7. PubMed ID: 12062286
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
[TBL] [Abstract][Full Text] [Related]
3. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue.
Dörr U; Räth U; Sautter-Bihl ML; Guzman G; Bach D; Adrian HJ; Bihl H
Eur J Nucl Med; 1993 May; 20(5):431-3. PubMed ID: 8100192
[TBL] [Abstract][Full Text] [Related]
4. Octreoscan in patients with bronchial carcinoid tumours.
Granberg D; Sundin A; Janson ET; Oberg K; Skogseid B; Westlin JE
Clin Endocrinol (Oxf); 2003 Dec; 59(6):793-9. PubMed ID: 14974924
[TBL] [Abstract][Full Text] [Related]
5. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
6. [Primary and follow-up studies of patients with carcinoid metastases using indium 111 octreotide--rational use of Sandostatin].
Lipp RW; Hammer HF; Passath A; Dobnig H; Ramschak-Schwarzer S; Stiegler C; Leb G; Krejs GJ
Acta Med Austriaca; 1993; 20(1-2):42-4. PubMed ID: 8475679
[TBL] [Abstract][Full Text] [Related]
7. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
8. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
9. Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment.
Fainstein Day P; Frohman L; Garcia Rivello H; Reubi JC; Sevlever G; Glerean M; Fernandez Gianotti T; Pietrani M; Rabadan A; Racioppi S; Bidlingmaier M
Pituitary; 2007; 10(3):311-9. PubMed ID: 17373589
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin analogue scintigraphy in carcinoid tumours.
Kwekkeboom DJ; Krenning EP; Bakker WH; Oei HY; Kooij PP; Lamberts SW
Eur J Nucl Med; 1993 Apr; 20(4):283-92. PubMed ID: 8491220
[TBL] [Abstract][Full Text] [Related]
11. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
Davì MV; Bodei L; Francia G; Bartolomei M; Oliani C; Scilanga L; Reghellin D; Falconi M; Paganelli G; Lo Cascio V; Ferdeghini M
J Endocrinol Invest; 2006 Jun; 29(6):563-7. PubMed ID: 16840837
[TBL] [Abstract][Full Text] [Related]
12. Use of somatostatin analog for localization and treatment of ACTH secreting bronchial carcinoid tumor.
Christin-Maitre S; Chabbert-Buffet N; Mure A; Boukhris R; Bouchard P
Chest; 1996 Mar; 109(3):845-6. PubMed ID: 8617102
[TBL] [Abstract][Full Text] [Related]
13. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
[TBL] [Abstract][Full Text] [Related]
14. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
[TBL] [Abstract][Full Text] [Related]
15. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature.
Leong WL; Pasieka JL
J Surg Oncol; 2002 Mar; 79(3):180-7. PubMed ID: 11870669
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.
Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B
Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177
[TBL] [Abstract][Full Text] [Related]
17. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up].
Igaz P; Rácz K; Tulassay Z
Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment of carcinoid syndrome in two cases of bronchial carcinoid].
Katakami N; Matsumoto H; Ishihara K; Umeda B
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Nov; 33(11):1313-8. PubMed ID: 8583728
[TBL] [Abstract][Full Text] [Related]
19. 111In-pentetreotide and 123I-MIBG for detection and resection of lymph node metastases of a carcinoid not visualized by CT, MRI or FDG-PET.
Yüksel M; Eziddin S; Ladwein E; Haas S; Biersack HJ
Ann Nucl Med; 2005 Oct; 19(7):611-5. PubMed ID: 16363628
[TBL] [Abstract][Full Text] [Related]
20. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
